Braveheart Bio BRVE 深 滬
等待開盤 09-24 09:30:00 美东时间
21.46
-2.150
-9.11%
華盛通- 最 高23.765
- 今 開23.21
- 成交量 52.17万股
- 最 低 21.31
- 昨 收 23.61
- 總市值 19.32亿
- 52周最高 32.00
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 21.31
- 委 比 43.43%
- 總股本 9003.90万
- 歷史最高 32.00
- 量 比 0.47
- 振 幅 10.40%
- 歷史最低 21.31
- 每 手 1
- 風險率 2.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Braveheart Bio Q2 EPS $(2.51)
Braveheart Bio (NASDAQ:BRVE) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $0.74 by 439.19 percent. This is a 1692.86 percent decrease over losses of $(0.14) per share from the same period last year.
09-09 04:37
Braveheart Bio, Inc. reports Q2 results
Braveheart Bio, Inc. press release (BRVE): Q2 Cash and cash equivalents were $122.8 million as of June 30, 2026, compared to $89.2 million as of December 31, 2025. Net loss was $15.0 million, and net ...
09-09 04:04
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio reported Q2 2026 financial results, highlighting $122.8M in cash and $527.3M post-IPO, supporting late-stage development of BHB-1893 for HCM. The company initiated Phase 3 LIONHEART-HCM trial for obstructive HCM and plans NOBLEHEART-HCM for non-obstructive HCM in 2027. BHB-1893 showed promising results in a Phase 2 trial, with improvements in cardiac biomarkers and diastolic function. R&D expenses were $11.1M, G&A $4.8M, with a net...
09-08 20:03
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
Stifel Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $45
Stifel analyst James Condulis initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $45.
08-31 18:26
美股周涨跌榜 | 心血管药企Braveheart Bio上市首周大升66.7%；多只绩优股飙升！IOVA周升逾55.8%，Atlassian周升逾47%
心血管药企Braveheart Bio上市首周大升66.7%；多只绩优股飙升！IOVA周升逾55.8%，季报营收创新高；Atlassian周升逾47%，第四财季营收同比增长27.6%>>
08-08 09:48
美股牛股 | 心血管药企BRVE上市首日飙涨逾65%，超预期募资3.8亿美元；IOVA大涨逾43%，赫兹租车涨近30%
心血管药企BRVE上市首日飙涨逾65%，超预期募资3.8亿美元；IOVA大涨逾43%，Q2亏损大幅收窄；赫兹租车涨近30%，Q2净利实现扭亏为盈>>
08-07 18:53
生物科技IPO热潮持续!心血管药企Braveheart(BRVE.US)募资扩大至3.825亿美元，发行价突破指引上限
生物科技公司Braveheart在美国IPO规模扩大后，筹集资金3.825亿美元。
08-06 16:28
Catalyst Watch: Jobs report, SpaceX's first report, AMD, and SK Hynix ratings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - August 3 ...
08-01 03:00
一周财经日历 | 7月大小非农重磅来袭；SpaceX迎首份财报+巨额解禁，汇丰、闪迪、Palantir、AMD财报轮番登场
美国7月大小非农数据重磅来袭；SpaceX迎首份财报+巨额解禁，汇丰、闪迪、Palantir、AMD财报轮番登场；拿森科技火热招股中>>
07-31 16:02
